SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating Middle East tensions and significant disruptions to the Strait of Hormuz drive oil prices to multi-year highs with historic weekly gains. Traders are fiercely debating whether this represents a sustainable "plumbing break" or an overextended "fear trade" ripe for a pullback, amidst discussions of potential US administration interventions to stabilize the market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Community excitement for Capricor Therapeutics is surging, driven by news of a key FDA official's departure, with many believing this removes a significant hurdle for Deramiocel's approval for Duchenne Muscular Dystrophy and could trigger a substantial short squeeze ahead of upcoming Phase 3 data presentation.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is trending after completing an AI licensing partnership in Africa, which, combined with its low float and extremely high cost-to-borrow, is fueling intense short squeeze speculation among traders. The community is actively discussing strong buy-side pressure and the stock's resilience amidst a broader red market, with many holding for significant upside.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is trending as the community speculates that the impending departure of a key FDA official could lead to a more favorable regulatory path for its Huntington's disease gene therapy, AMT-130, after prior setbacks. This has sparked intense debate between those anticipating accelerated approval for gene therapies and bears who remain skeptical of the underlying drug data and the sustainability of the rally.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending with surging volume, fueled by intense short-covering and bullish community sentiment. Investors are optimistic about a significant re-rating, citing recent analyst upgrades, M&A buzz in the oncology sector, and anticipated data readouts for its promising TIL therapy platform.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences (SLS) is gaining significant attention after its CEO highlighted potential "curative outcomes" for AML with GPS and SLS009, reinforcing expectations of extended patient survival in the REGAL trial and fueling widespread community speculation of an impending buyout and substantial short squeeze.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing extreme volatility, drawing polarized community sentiment between dip-buyers confident in long-term AI demand and short-sellers citing geopolitical concerns and the ETF's repeated failure to break key resistance. The leveraged semiconductor fund is seeing rapid swings, driven by mixed reactions to sector earnings and broader market uncertainty.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is trending after the FDA accepted its resubmitted BLA for RP1 in advanced melanoma, setting an April 10, 2026 PDUFA date and reigniting investor confidence following previous regulatory hurdles. The community is actively discussing the potential for approval and significant analyst price target upgrades, while some express caution regarding the long timeline and potential for dilution.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending following reports of potential massive commercial jet orders from China and escalating defense contract opportunities, yet community sentiment is mixed between those anticipating a significant rally and skeptics of its historical muted response to positive catalysts.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum is drawing significant attention following its S&P 500 inclusion, which is expected to drive institutional buying, and a substantial $2 billion investment from NVIDIA to secure advanced optical technology for AI data centers. While many are bullish on LITE's pivotal role in AI infrastructure, a segment of the community debates its rapid, "parabolic" valuation and the potential for a sharp correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top Penny Stocks To Follow Now - January 6th

Sidus Space, Envirotech Vehicles, Autozi Internet Technology (Global), Cyclerion Therapeutics, and Datavault AI are the five Penny stocks to watch today, according to MarketBeat's stock screener...

Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Cyclerion Therapeutics shares jumped 47% in after-hours trading on Tuesday, placing it among the session’s top five U.S. gainers, after the company said it will relaunch with a focus on developing therapies for neuropsychiatric conditions.The plan is supported by a new licensing agreement with the Massachusetts Institute of Technology (MIT) covering intellectual property that will form the basis of its research programs.The company stated its lead program is for treatment-resistant depression (TRD) and is a combination of anesthetic agents with a proprietary delivery system to restore connectivity between regions of the brain. A Phase 2 proof-of-concept trial is expected to commence in 2026 with data anticipated in 2027.Cyclerion was spun out of Ironwood Pharmaceuticals in 2019. It raised $175 million in private investment to develop its soluble guanylate cyclase (sGC) stimulator programs.&nbsp;As part of its strategic shift since then, the company sold zagociguat and CY3018 to Tisento in 2023, out-licensed praliciguat in 2021, and entered into a license option agreement for olinciguat in 2024.“This relaunch represents a pivotal moment for Cyclerion Therapeutics as we refocus our efforts on advancing breakthrough neuropsychiatric treatments for patients who have limited therapeutic options today,” said Errol DeSouza, Chairperson of Cyclerion’s Board of Directors.CEO Regina Graul said the company plans to expand into additional neuropsychiatric diseases as it builds a pipeline of novel therapies.On Stocktwits, retail sentiment was ‘extremely bullish’ amid an 842% surge in 24-hour message volume. One bullish user called Cyclerion a strong candidate for a squeeze when regular trading resumes on Wednesday.&nbsp;<stembedurl>https://stocktwits.com/carldcarpatst/message/629757983</stembedurl>Another user stated that they had been accumulating shares over the past year, citing the MIT licensing deal as validation of the company’s potential and predicting a market cap of $100 million if further announcements follow.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/629746974</stembedurl><a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics’ stock</a> has declined 6.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cyclerion Therapeutics’ stock (CYCN) has declined 6.2% so far in 2025. (Photo credit: Getty Images)

Why Did Cyclerion Therapeutics Stock Surge Nearly 50% After-Hours Today?

The biotech is relaunching as a neuropsychiatric company, anchored by an MIT licensing deal and a lead program in treatment-resistant depression.

Equity

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

CYCN
Cyclerion Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CYCN News

CYCNCyclerion Therapeutics Inc